

# Beta-alanine supplementation in patients with chronic obstructive pulmonary disease (COPD) following a neuromuscular electrical stimulation (NMES) training program.

Gepubliceerd: 02-03-2020 Laatste bijgewerkt: 15-05-2024

It is hypothesized that beta-alanine supplementation in patients with COPD following a neuromuscular electrical stimulation (NMES) training program (as part of pulmonary rehabilitation; PR) will increase muscle carnosine levels, which in turn will...

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving nog niet gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON25510

### Bron

NTR

### Verkorte titel

BASE-ELECTRIC

### Aandoening

Chronic obstructive pulmonary disease (COPD); Exercise intolerance; Muscle dysfunction.

## Ondersteuning

**Primaire sponsor:** Board of Directors CIRO

**Overige ondersteuning:** Lung Foundation, the Netherlands

## Onderzoeksproduct en/of interventie

# Uitkomstmaten

## Primaire uitkomstmaten

Exercise tolerance, defined as cycle endurance time. Cycle endurance time will be determined with the constant work-rate test (CWRT), performed on an ergometer at 75% of the maximal work rate (pre-determined by a cardiopulmonary exercise test; CPET) to volitional exhaustion.

## Toelichting onderzoek

### Achtergrond van het onderzoek

Exercise intolerance is common in patients with chronic obstructive pulmonary disease (COPD) and, although multifactorial, it is largely caused by lower-limb muscle dysfunction. Research has shown that patients with severe to very severe COPD have significantly lower levels of muscle carnosine, which acts as a pH buffer and antioxidant. Beta-alanine is the rate-limiting precursor to carnosine synthesis and BA supplementation has been shown to consistently elevate muscle carnosine in a variety of populations. Hence, it is very plausible to hypothesize that beta-alanine supplementation in COPD patients following a neuromuscular electrical stimulation (NMES) training program (as part of pulmonary rehabilitation; PR) will increase muscle carnosine levels, which in turn will result in a positive effect on exercise tolerance and lower-limb muscle function.

### Doel van het onderzoek

It is hypothesized that beta-alanine supplementation in patients with COPD following a neuromuscular electrical stimulation (NMES) training program (as part of pulmonary rehabilitation; PR) will increase muscle carnosine levels, which in turn will result in a positive effect on exercise tolerance and lower-limb muscle function. These adaptations may translate into improved functional capacity during activities of daily living and improved quality of life.

The primary targets of both exercise training and BA supplementation are the muscles of ambulation. Nevertheless, it seems reasonable to hypothesize that an enhanced bio-availability of carnosine in the body, by means of beta-alanine supplementation, may have an anti-oxidative effect in both the lungs and the brain.

### Onderzoeksopzet

The regular PR program at CIRO consists of a baseline assessment, followed by an inpatient PR program and is ended with a post-rehabilitation assessment. After completion of the baseline assessment and obtaining informed consent, an additional study-related appointment is scheduled with included patients approximately 1 week prior to the start of the PR program. This additional testing day will be repeated after the rehabilitation period.

Study duration per subject will be approximately 10 to 12 weeks.

During the regular (baseline and post) assessments, the following outcomes will be measured: exercise capacity and endurance, quadriceps muscle function, body composition, physical activity, functional mobility, dyspnoea, health-related quality of life, anxiety and depression, fatigue, problematic activities of daily life, pulmonary function and patient characteristics.

The study-related appointments include: fasting venous blood sampling, a vastus lateralis muscle biopsy (optional, not required), two cognitive function tests (M-WCST and SCWT) and two tests for lung inflammatory biomarkers (VOC and FeNO measurements).

During the PR program 80 sessions of high-frequency NMES (75Hz), being the primary exercise modality, will be applied. Patient safety and compliance will be constantly monitored during the PR program.

### **Onderzoeksproduct en/of interventie**

Oral beta-alanine (sustained-release Carnosyn®; 3.2 g/day) or identical looking placebo supplementation for a duration of 8-10 weeks.

## **Contactpersonen**

### **Publiek**

CIRO Horn  
Roy Meys

+31 (0)475 587 602

### **Wetenschappelijk**

CIRO Horn  
Roy Meys

+31 (0)475 587 602

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen**

## (Inclusiecriteria)

- COPD, GOLD group B or D
- Modified Medical Research Council (mMRC) dyspnoea score  $\geq 3$
- Clinically stable according to the pulmonary physician, i.e. no exacerbation and/or hospitalization within the previous 4 weeks.
- Age between 40-80 years
- Cycle endurance time is 100-300 seconds.
- Quadriceps muscle strength  $< 80\%$  predicted
- Attending the regular inpatient pulmonary rehabilitation program in CIRO and receiving NMES as the primary muscle training modality.

## Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Patients will be excluded if they meet at least one of the following criteria: instable cardiac disease, use of anabolic steroids during PR program, history of drugs/alcohol abuse, vegetarianism, inability to understand the Dutch language, self-reported beta-alanine supplementation in the past 3 months, participation in a PR program within the past 12 months, inability to perform a cardiopulmonary exercise test.

## Onderzoeksopzet

### Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Dubbelblind
Controle:	Placebo

### Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-04-2020
Aantal proefpersonen:	68
Type:	Verwachte startdatum

## Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

**Wordt de data na het onderzoek gedeeld:** Nog niet bepaald

### Toelichting

N/A

## Ethische beoordeling

Positief advies

Datum: 02-03-2020

Soort: Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 56353

Bron: ToetsingOnline

Titel:

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL8419
CCMO	NL68757.091.19
OMON	NL-OMON56353

## Resultaten

### Samenvatting resultaten

N/A